Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of LY4175408 in Participants With Advanced Cancer
- Conditions
- Neoplasm MetastasisTriple Negative Breast CancerCarcinoma, Non-Small-Cell LungSmall Cell Lung CarcinomaEndometrial Neoplasms
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 240
- Registration Number
- NCT07046923
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute, Orlando, Florida, United States
🇺🇸Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants
- Conditions
- HealthyCancer
- First Posted Date
- 2025-07-01
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 104
- Registration Number
- NCT07046559
- Locations
- 🇬🇧
Fortrea Clinical Research Unit, Holbeck, Leeds, United Kingdom
A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants
- First Posted Date
- 2025-06-29
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 120
- Registration Number
- NCT07044271
- Locations
- 🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States
🇺🇸ICON, Salt Lake City, Utah, United States
A Study of [14C]-LY4065967 in Healthy Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT07039045
- Locations
- 🇺🇸
Fortrea Clinical Research Unit, Madison, Wisconsin, United States
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
- Conditions
- ObesityOverweightChronic Low Back Pain (CLBP)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 586
- Registration Number
- NCT07035093
- Locations
- 🇺🇸
MD First Research - Chandler, Chandler, Arizona, United States
🇺🇸Tucson Orthopaedic Institute - North Wyatt Drive, Tucson, Arizona, United States
🇺🇸Ark Clinical Research - Fountain Valley, Fountain Valley, California, United States
A Study of LY3985863 in Healthy Participants
- First Posted Date
- 2025-06-22
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT07030127
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes
- Conditions
- ObesityOverweightType 2 Diabetes
- Interventions
- Drug: LY6249492Drug: Placebo
- First Posted Date
- 2025-06-22
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 150
- Registration Number
- NCT07030868
- Locations
- 🇺🇸
HOPE Research Institute, Phoenix, Arizona, United States
🇺🇸Headlands Research - Scottsdale, Scottsdale, Arizona, United States
🇺🇸The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson, Arizona, United States
A Study of LY3867070 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: LY3867070Drug: Placebo
- First Posted Date
- 2025-06-15
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 196
- Registration Number
- NCT07021547
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸Fortrea Clinical Research Unit, Dallas, Texas, United States
A Master Protocol of Multiple Interventions for the Treatment of Adults With Moderate-to-Severe Atopic Dermatitis.
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 317
- Registration Number
- NCT07020351
- Locations
- 🇺🇸
Johnson Dermatology, Fort Smith, Arkansas, United States
🇺🇸Arkansas Research Trials, North Little Rock, Arkansas, United States
🇺🇸Dermatology Research Associates, Los Angeles, California, United States
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 200
- Registration Number
- NCT07006792
- Locations
- 🇺🇸
Total Skin & Beauty Dermatology Center, PC DBA Total Dermatology, Birmingham, Alabama, United States
🇺🇸Dermatology Research Associates, Los Angeles, California, United States
🇺🇸Leading Edge Dermatology, Plantation, Florida, United States